Genentech: FDA Approves Tecentriq Plus Chemotherapy for Some Non-Small Cell Lung Cancer

Date : 12/04/2019 @ 12:21AM
Source : Dow Jones News
Stock : Roche Holding (QX) (RHHBY)
Quote : 42.45  0.03 (0.07%) @ 8:46PM

Genentech: FDA Approves Tecentriq Plus Chemotherapy for Some Non-Small Cell Lung Cancer

Roche Holding (QX) (USOTC:RHHBY)
Historical Stock Chart

2 Months : From Nov 2019 to Jan 2020

Click Here for more Roche Holding (QX) Charts.
   By Stephen Nakrosis 
 

Genentech said Tuesday the Food and Drug Administration approved its Tecentriq plus chemotherapy to treat certain lung cancers.

The company said the approval was for the initial treatment of certain adults with metastatic non-squamous non-small cell lung cancer.

Genentech said the approval was based on results from a Phase III study that showed Tecentriq, or atezolizumab, "in combination with chemotherapy helped people live significantly longer compared to chemotherapy alone."

Genentech is a member of the Roche Group.

 

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

December 03, 2019 19:06 ET (00:06 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest RHHBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.